Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

Early poliferative diabetic retinopathy Neovascularization of the disc or elsewhere, which does not meet the high-risk characteristics High-risk proliferative diabetic retinopathy Moderate or ...

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to ...

Patients with diabetes may not need to have a HbA1c value lower than 8% before cataract surgery to reduce the risk for endophthalmitis.

an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...